Predicting the in vitro toxicity of synthetic beta-amyloid (1-40) - PubMed (original) (raw)
Predicting the in vitro toxicity of synthetic beta-amyloid (1-40)
S K Brining. Neurobiol Aging. 1997 Nov-Dec.
Abstract
The in vitro toxicity of synthetic beta-amyloid (betaA4) is variable and unpredictable, limiting its use as a research tool. This study describes a method using Congo red (CR) to predict the in vitro toxicity of betaA4 solutions. Histopathologically, CR is used to stain the neuritic, betaA4-containing plaques, one of the hallmarks of Alzheimer's disease. In this study, synthetic betaA4 solutions were incubated with CR at a molar ratio of 1.0:2.5. The solutions were centrifuged and the absorbance of the supernatants were measured. Predictions of nontoxicity correlated with absorbance readings near zero. Toxicity was evaluated relative to control cells (vehicle only), using a hemocytometer to count PC-12 cells that excluded trypan blue. The positive predictive value of the test was 78% and the negative predictive value was 100%. To use this test, the toxic concentration(s) of betaA4 must first be established empirically. Then, the CR test can be used to evaluate the potential toxicity of betaA4 solutions at similar concentrations. Thus, this test can be used under a variety of laboratory circumstances.
Similar articles
- Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion.
Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. Pollack SJ, et al. Neurosci Lett. 1995 Sep 15;197(3):211-4. doi: 10.1016/0304-3940(95)11939-t. Neurosci Lett. 1995. PMID: 8552301 - Gel electrophoretic distinction between toxic and nontoxic forms of beta-amyloid (1-40).
Brining SK, Chen N, Yi D, Chrambach A. Brining SK, et al. Electrophoresis. 1999 Jun;20(7):1398-402. doi: 10.1002/(SICI)1522-2683(19990601)20:7<1398::AID-ELPS1398>3.0.CO;2-1. Electrophoresis. 1999. PMID: 10424461 - Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.
Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. Pollack SJ, et al. Neurosci Lett. 1995 Jan 23;184(2):113-6. doi: 10.1016/0304-3940(94)11182-i. Neurosci Lett. 1995. PMID: 7724043 - Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Walsh DM, et al. Biochem Soc Trans. 2002 Aug;30(4):552-7. doi: 10.1042/bst0300552. Biochem Soc Trans. 2002. PMID: 12196135 Review.
Cited by
- Single-particle characterization of Aβ oligomers in solution.
Yusko EC, Prangkio P, Sept D, Rollings RC, Li J, Mayer M. Yusko EC, et al. ACS Nano. 2012 Jul 24;6(7):5909-19. doi: 10.1021/nn300542q. Epub 2012 Jun 21. ACS Nano. 2012. PMID: 22686709 Free PMC article. - Abeta aggregation and possible implications in Alzheimer's disease pathogenesis.
Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Bharadwaj PR, et al. J Cell Mol Med. 2009 Mar;13(3):412-21. doi: 10.1111/j.1582-4934.2009.00609.x. J Cell Mol Med. 2009. PMID: 19374683 Free PMC article. Review. - Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease.
Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Dineley KT, et al. J Neurosci. 2001 Jun 15;21(12):4125-33. doi: 10.1523/JNEUROSCI.21-12-04125.2001. J Neurosci. 2001. PMID: 11404397 Free PMC article. - Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation.
Moon MH, Jeong JK, Seo JS, Seol JW, Lee YJ, Xue M, Jackson CJ, Park SY. Moon MH, et al. Exp Mol Med. 2011 Mar 31;43(3):138-45. doi: 10.3858/emm.2011.43.3.016. Exp Mol Med. 2011. PMID: 21297379 Free PMC article.